Biopharmaceutical company Gilead Sciences Inc (NASDAQ: GILD) Wednesday said its third-quarter earnings increased, aided by higher revenues. The results also exceeded the market’s prediction. Adjusted earnings increased 29% to $2.11 per share from $1.64 per share a year earlier. Analysts were looking for a smaller bottom-line number. Net income, on an unadjusted basis, came in at $360 million or $0.29 per share, compared to a loss of $1.17 billion or $0.92 per share in the prior-year period. Revenues moved up 17% year-over-year to $6.58 billion in the September-quarter and exceeded the market’s prediction. The company’s stock closed Wednesday’s regular trading lower, hut gained during the after-hours session

Corporate Participants:

Douglas Maffei — Senior Director, Investor Relations

Daniel O’Day — Chairman and Chief Executive Officer

Johanna Mercier — Chief Commercial Officer

Merdad Parsey — Chief Medical Officer

Andrew Dickinson — Chief Financial Officer

Diana Brainard — Senior Vice President, HIV and Emerging Viral Infections

---

Send in a voice message: https://anchor.fm/earningspodcast/message Support this podcast: https://anchor.fm/earningspodcast/support